DR REDDYS LABORATORIES LTD

Dr. Reddy's Laboratories Ltd. announced the resignation of Mr. Deepak Sapra from his position as CEO, API and Services, and Senior Management Personnel. His last day of employment will be November 12, 2026. Mr. Sapra is departing to pursue opportunities outside the company, having served Dr. Reddy's for over 23 years.

Dr. Reddy's Laboratories announced that the U.S. Food and Drug Administration (FDA) has approved its rituximab biosimilar for the U.S. market. This approval significantly strengthens the company's global biosimilars portfolio and advances its business in the United States. Under a commercialization agreement, Fresenius Kabi will exclusively commercialize the product in the U.S. The rituximab biosimilar has already been commercialized in India, the European Union, the United Kingdom, and over 25 emerging markets.

DR. REDDY’S LABORATORIES LIMITED filed a Form 6-K with the SEC, which includes an intimation dated July 29, 2026. The specific details of the intimation are not provided in this filing.

Dr. Reddy's Laboratories reported Q1 FY27 consolidated revenues of $853 million, a 5.6% year-over-year decline, primarily due to lower lenalidomide sales and a $28 million provision for semaglutide API challenges. The underlying base business, excluding lenalidomide, showed healthy double-digit growth across key geographies. EBITDA margin was 12.5%, or 15.4% excluding the semaglutide provision. The company expects semaglutide supplies to resume by November and remains confident in a strong second half of the fiscal year.

Dr. Reddy's Laboratories Limited announced that its members approved three key resolutions at the 42nd Annual General Meeting. These include the re-appointment of Dr. K P Krishnan as an Independent Director for a second five-year term and the appointment of Mr. Srikanth Velamakanni as a new Independent Director for a five-year term. Additionally, M/s Deloitte Haskins & Sells, LLP were appointed as the Statutory Auditors for a five-year term.

Dr. Reddy's Laboratories Ltd. announced the outcome of its 42nd Annual General Meeting (AGM) held on July 23, 2026. All resolutions presented to the members were passed by the requisite majority. Key approvals included the adoption of financial statements for FY2025-26, the declaration of a final dividend of Rs. 8 per equity share, and the appointment/re-appointment of directors and auditors.

Dr. Reddy's Laboratories Limited announced the appointment of Deloitte Haskins & Sells, LLP as its new statutory auditors and Independent Registered Public Accounting Firm. This change is in compliance with the Indian Companies Act, 2013, which requires auditor rotation. Deloitte will serve for five consecutive years, subject to shareholder approval. The company confirmed there were no disagreements or reportable events with the previous auditor, Ernst & Young Associates LLP.

Dr. Reddy's Laboratories Limited announced that Ernst & Young Associates LLP completed their review of the company's condensed consolidated interim financial statements for the three months ended June 30, 2026 and 2025. The auditors reported that they are not aware of any material modifications that should be made for the statements to conform with International Accounting Standard (IAS) 34. This follows an unqualified audit opinion issued on the company's consolidated financial statements as of March 31, 2026.

Dr. Reddy's Laboratories reported Q1FY27 consolidated revenues of ₹80,705 million, a 5.6% decrease year-over-year but a 7.4% increase quarter-over-quarter. Profit after tax attributable to equity holders was ₹4,435 million, down 69% YoY but up 102% QoQ, significantly impacted by a ₹2,397 million provision for semaglutide API-related costs. The company also appointed Dr. Sridevi Khambhampaty as Global Head of Biologics and Senior Management Personnel, and M/s Deloitte Haskins & Sells, LLP as its Independent Registered Public Accounting Firm.

Dr. Reddy's Laboratories has appointed Dr. Sridevi Khambhampaty as Global Head of Biologics and Senior Management Personnel, effective July 22, 2026. She will also join the Management Council, bringing over two decades of biopharmaceutical experience. Additionally, the company confirmed the appointment of M/s Deloitte Haskins & Sells, LLP as its Independent Registered Public Accounting Firm for SEC filings, aligning with their prior appointment as Statutory Auditors.